Morgan Stanley initiated coverage of Staar Surgical with an Equal Weight rating and $35 price target. The firm values Staar at a valuation in-line with other fast growing MedTech peers in the 15-20% growth range, the analyst tells investors. While Staar differentiates itself by being more profitable than most, the firm feels this is partly offset by country risk premium for the lower visibility in the China market, the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STAA:
- Insider Trading: Staar Surgical’s (NASDAQ:STAA) Major Insider Is Buying the Dip
- Insider Trading: Staar Surgical’s (NASDAQ:STAA) Major Insider Continues to Shower Love
- Staar Surgical price target lowered to $55 from $58 at Mizuho
- Staar Surgical price target lowered to $40 from $45 at Piper Sandler
- Staar Surgical reports Q3 adjusted EPS 37c, consensus 18c